$SGMT

Sagimet Biosciences (SGMT) reported Q2 2026 results, with R&D expenses rising to $11.5M and net loss widening to $14.0M. The company has $257.6M in cash, expected to fund operations through 2028. Analysts have differing views on its Phase 3 trial for denifanstat, with Goldman Sachs giving a Sell rating and Barclays/Cantor Fitzgerald bullish. Hedge fund ownership increased, and short interest slightly eased.

United Therapeutics (UTHR) and Sagimet Biosciences (SGMT) shares declined after Goldman Sachs resumed coverage with Sell ratings. Goldman initiated coverage of UTHR with a Sell rating.

Analysts upgraded five companies: Barclays raised Sagimet Biosciences (SGMT) to Overweight, targeting $18. B of A upgraded Figure Technology (FIGR) to Neutral, targeting $49. UBS upgraded Illumina (ILMN) to Buy, targeting $260. Wells Fargo upgraded Martin Marietta (MLM) to Overweight, targeting $609. UBS also upgraded Waters (WAT) to Buy, targeting $490.

Analysts initiated coverage on several companies: StoneX started HOOD with a Buy and $170 target, HC Wainwright began TLSI with a Buy and $11 target, Needham initiated KDK with a Buy and $8 target, BMO rated DECK Underperform with a $70 target, and Cantor Fitzgerald gave SGMT an Overweight rating.

Sagimet Biosciences (SGMT) announced its Phase 3 AURORA trial for denifanstat, a treatment for moderate to severe acne, is on track to begin enrollment in Q4 2026. The trial will involve 800 U.S. patients, with results expected to support a New Drug Application submission. Denifanstat previously succeeded in a Phase 3 trial in China. SGMT's stock closed at $10.21, down 0.38%.

Kemble George sold 350,987 shares of Sagimet Biosciences Inc. (SGMT) at $10.23 ($3.59M total) on 2026-08-14 under a Rule 10b5-1 trading plan.

Sagimet Biosciences (Nasdaq: SGMT) said the FDA cleared its IND and issued a “Study May Proceed” letter for denifanstat, a Phase 3 FASN inhibitor for moderate to severe acne. The trial is planned to start in 2H 2026, enrolling about 800 U.S. patients (450 adolescents). Dosing is 50 mg once daily vs placebo for 12 weeks, with a 40-week open-label extension.

Sagimet Biosciences (SGMT) shares rose 3.4% pre-open to $9.84 after Q2 2026 results. The company reported a net loss of $14.0 million for the quarter ended June 30, slightly better than consensus, and reaffirmed its denifanstat pipeline. It cited Phase 3 data from Ascletis in China showing about a 20-point improvement vs placebo, with no serious adverse events, and plans a U.S. Phase 3 trial enrolling 800 patients starting H2 2026. Analysts rate it Strong Buy with a $28.50 average 12-month targe

Sagimet Biosciences (SGMT) reported Q2 net loss widening to $14.0M from $10.4M a year earlier. As of June 30, 2026, it had $257.6M cash, expected to fund operations through 2028. The company plans a U.S. Phase 3 registrational trial of denifanstat for moderate-to-severe acne in H2 2026 and a Phase 2 for TVB-3567 after its Phase 1.

Sagimet Biosciences (Nasdaq: SGMT) reported Q2 2026 results and updates. It plans to initiate a U.S. registrational Phase 3 for denifanstat in moderate to severe acne in 2H 2026. First-in-human Phase 1 for FASN inhibitor TVB-3567 is ongoing. In April 2026 it raised $175.0M gross. Cash and marketable securities were $257.6M at June 30, 2026, funding operations through 2028.